Head-To-Head Contrast: Liquidia (NASDAQ:LQDA) vs. TherapeuticsMD (NASDAQ:TXMD)

TherapeuticsMD (NASDAQ:TXMD) and Liquidia (NASDAQ:LQDA) are both healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their risk, valuation, analyst recommendations, profitability, earnings, dividends and institutional ownership.

Institutional and Insider Ownership

30.7% of TherapeuticsMD shares are held by institutional investors. Comparatively, 64.5% of Liquidia shares are held by institutional investors. 1.7% of TherapeuticsMD shares are held by company insiders. Comparatively, 25.6% of Liquidia shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Risk & Volatility

TherapeuticsMD has a beta of 0.65, suggesting that its stock price is 35% less volatile than the S&P 500. Comparatively, Liquidia has a beta of 0.53, suggesting that its stock price is 47% less volatile than the S&P 500.

Analyst Recommendations

This is a summary of current ratings for TherapeuticsMD and Liquidia, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
TherapeuticsMD	1	0	0	0	1.00
Liquidia	2	3	5	1	2.45

Liquidia has a consensus target price of $98.08, suggesting a potential upside of 42.92%. Given Liquidia’s stronger consensus rating and higher possible upside, analysts clearly believe Liquidia is more favorable than TherapeuticsMD.

Valuation & Earnings

This table compares TherapeuticsMD and Liquidia”s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
TherapeuticsMD	$3.02 million	8.58	-$570,000.00	$0.02	112.00
Liquidia	$158.32 million	38.80	-$68.92 million	$1.37	50.09

TherapeuticsMD has higher earnings, but lower revenue than Liquidia. Liquidia is trading at a lower price-to-earnings ratio than TherapeuticsMD, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares TherapeuticsMD and Liquidia’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
TherapeuticsMD	-6.64%	-1.09%	-0.78%
Liquidia	30.74%	149.65%	36.30%

Summary

Liquidia beats TherapeuticsMD on 12 of the 15 factors compared between the two stocks.

About TherapeuticsMD

TherapeuticsMD, Inc. operates as a pharmaceutical royalty company in the United States. It has a license agreement with Mayne Pharma to commercialize the IMVEXXY, BIJUVA, and ANNOVERA prescription prenatal vitamin products sold under the BocaGreenMD and vitaMedMD brand names. The company sells its prescription pharmaceutical products and prenatal vitamin products through wholesale distributors and retail pharmacy distributors. TherapeuticsMD, Inc. was founded in 2008 and is headquartered in Boca Raton, Florida.

About Liquidia

Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its lead product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). The company also offers Remodulin, a treprostinil administered through continuous intravenous and subcutaneous infusion. The company also a license agreement with Pharmosa Biopharm Inc to develop and commercialize L606, an inhaled sustained-release formulation of Treprostinil for the treatment of PAH and PH-ILD. Liquidia Corporation was founded in 2004 and is headquartered in Morrisville, North Carolina.